Advertisement

Digestive Diseases and Sciences

, Volume 53, Issue 3, pp 836–843 | Cite as

Biological Treatment for Liver Tumor and New Potential Biomarkers

  • Maurizio Chiriva-Internati
  • Fabio Grizzi
  • Mitchell S. Wachtel
  • Marjorie Jenkins
  • Raffaele Ferrari
  • Everardo Cobos
  • Eldo E. Frezza
Original Paper

Abstract

The search for effective and efficacious therapy for liver tumor was started many years ago and is still ongoing. Despite all of the surgical advances, much work needs to be done to improve understanding of the biology of the tumor and its treatment. The rules of hepatic surgery are changing because of two recent major trends: (1) technical simplification, and (2) the endeavor to treat an increasing number of patients. T lymphocytes are potent cellular effectors of the immune system and possess a memory that responds to rechallenge by the same antigen. Being more specific and less toxic than chemotherapy, tumor infusion could be an ideal adjuvant therapy for patients with primary and secondary liver malignancies. Moreover, tumor cell vaccines have demonstrated efficacy in terms of minimal residual disease and are being investigated, but the requirement for an adequate supple of autologos tumor may limit the general applicability of these approaches. Various studies have demonstrated the aberrant expression of germ-cell proteins called cancer-testis (CT) antigens in liver neoplastic cells. Their selective normal-tissue expression makes them ideal antigens for immune targeting of malignant disease. Specific expression of CT antigens also suggests their application as tumor markers to detect circulating hepatocellular carcinoma (HCC) cells, as an adjuvant diagnostic tool, and as indicators for recurrence and prognosis. Biological therapy is now generating more clinical trials. More studies need to be performed and further experiments need to be done, although currently this seems a valid pathway for the treatment of liver cancer. Cytoreduction treatment of liver tumor and the vaccine might be the future of the treatment of primary and secondary liver tumor.

Keywords

Liver Tumors Surgery CTL Cytoreduction Immunotherapy Biological therapy Cancer-testis antigens Biomarkers 

Notes

Acknowledgements

The present study is supported by the Institutional Research Program of the Texas Tech University Health Sciences Center and Southwest Cancer Treatment and Research Center program.

References

  1. 1.
    Foster JH (1991) History of liver surgery. Arch Surg 126:381–387PubMedGoogle Scholar
  2. 2.
    Lav WY (1997) This history of liver surgery. J R Coll Surg Edinb 42:303–309Google Scholar
  3. 3.
    Hardy KJ (1990) Liver surgery the past 2000 years. Aust NZ J Surg 60:811–817CrossRefGoogle Scholar
  4. 4.
    Vivarelli M, Guglielmi A, Ruzzenente A, Cucchetti A, Bellusci R, Cordiano C, Cavallari A (2004) Surgical resection versus percutaneous RFA in the treatment of hepatocellular carcinoma in cirrhotic liver. Ann Surg 2:120–127Google Scholar
  5. 5.
    Carr BI, Selby R, Madariaga J, Iwatsuki S, Starzl TE (1993) Prolonged survival after liver transplantation and cancer chemotherapy for advanced-stage hepatocellular carcinoma. Trans Proc 25:1124–1125Google Scholar
  6. 6.
    Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT (1998) NIH conference on hepatocellular carcinoma. Ann Intern Med 108:390–401Google Scholar
  7. 7.
    Di Bisceglie A (1989) Hepatocellular carcinoma: molecular biology of its growth and relationship to hepatitis B virus infection. Med Clin North Am 73:985–995PubMedGoogle Scholar
  8. 8.
    Tsuzuki T, Sugioka A, Udea M (1990) Hepatic resection for hepatocellular carcinoma. Surgery 107:511–520PubMedGoogle Scholar
  9. 9.
    Curley SA, Izzo F, Delrio P, Ellis LM, Granchi J, Vallone P, Fiore F, Pignata S, Daniele B, Cremona F (1999) Radiofrequency ablation of unresectable primary and metastatic hepatic malignancies: results in 123 patients. Ann Surg 230:1–8PubMedCrossRefGoogle Scholar
  10. 10.
    Frezza EE (2004) Therapeutic management algorithm in cirrhotic and non-cirrhotic patients in primary or secondary liver masses. Dig Dis Sci 49:866–871PubMedCrossRefGoogle Scholar
  11. 11.
    Frezza EE (2004) Laparoscopic radiofrequency ablation of solitary hepatic gastrinoma metastases. Dig Dis Sci 49:224–227PubMedCrossRefGoogle Scholar
  12. 12.
    Frezza EE, Wachtel MS, Barragan B, Chiriva-Internati M, Cobos E (2007) The role of radiofrequency ablation in multiple liver metastases to debulk the tumor: a pilot study before alternative therapies. J Laparoendose Adv Surg Tech A 17:282–284CrossRefGoogle Scholar
  13. 13.
    Chiriva-Internai M, Grizzi F, Cobos E, Jumper C, Hermonat PL, Frezza EE (2005) Immunological treatment of liver tumours. World J Gastroenterol 11:6571–6576Google Scholar
  14. 14.
    Rhim H, Dodd G (1999) Radiofrequency thermal ablation of liver tumours. J Clin Ultrasound 5:221–229CrossRefGoogle Scholar
  15. 15.
    Rossi S, Formari F, Paties C, Buscarini L (1990) Thermal lesions induced by 480-KHz localized current field in guinea pigs and in pig livers. Tumouri 76:54–57Google Scholar
  16. 16.
    Curley SA, Izzo F, Ellis LM, Nicolas Vauthey J, Vallone P (2000) Radiofrequency ablation of hepatocellular cancer in 110 patients with cirrhosis. Ann Surg 232:381–391PubMedCrossRefGoogle Scholar
  17. 17.
    Ellis LM, Chase J, Patt Y, Curley SA (1998) Hepatic arterial chemotherapy for colorectal cancer liver metastasis. In: Curley SA (ed) Liver Cancer. Springer Verlag Publishers, New York, pp 150–172Google Scholar
  18. 18.
    Norazmi MN, Hohmann AW, Skinner JM, Jarvis LR, Bradley J (1990) Density and phenotype of tumour-associated mononuclear cells in colonic carcinomas determined by computer-assisted video image analysis. Immunology 69:282–286PubMedGoogle Scholar
  19. 19.
    Morgan RA, Dudley ME, Wunderlich JR, Hughes MS, Yang JC, Sherry RM, Royal RE, Topalian SL, Kammula US, Restifo NP, Zheng Z, Nahvi A, de Vries CR, Rogers-Freezer LJ, Mavroukakis SA, Rosenberg SA (2006) Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314:126–129PubMedCrossRefGoogle Scholar
  20. 20.
    Bouwens L, Wise E (1989) Hepatic pit cells have natural cytotoxic (NC) activity against solid tumour derived target cells. In: Wisse E, Knook DL, Decker K (eds) The Netherlands cells of the hepatic sinusoid. Kupffer Cell Foundation, Rijswijk, pp 215–220Google Scholar
  21. 21.
    Takagi S, Chen K, Schwarz R, Iwatsuki S, Herberman RB, Whiteside TL (1989) Functional and phenotypic analysis of tumour infiltrating lymphocytes isolated from human primary and metastatic liver tumours and cultured in recombinant interleukin-2. Cancer 63:102–111PubMedCrossRefGoogle Scholar
  22. 22.
    Bayon LG, Izquierdo MA, Sirovich I, van Rooiien N, Beelen RH, Meijer S (1996) Role of Kupffer cells in arresting circulating tumour cells and controlling metastatic growth in the liver. Hepatology 23:1224–1231PubMedCrossRefGoogle Scholar
  23. 23.
    Kurokohchi K, Carrington M, Mann DL, Simonis TB, Alexander-Miller MA, Feinstone SM, Akatsuka T, Berzofsky JA (1996) Expression of HLA class I molecules and the transporter associated with antigen processing in hepatocellular carcinoma. Hepatology 23:1181–1188PubMedCrossRefGoogle Scholar
  24. 24.
    Garrido F, Gabrera T, Lopez-Nevok MA, Ruiz-Cabello F (1995) HLA class I antigens in human tumours. Adv Cancer Res 67:155–195PubMedCrossRefGoogle Scholar
  25. 25.
    Momberg F, Koch S (1989) Selective loss of 32-microglobulin mRNA in human colon carcinoma. J Exp Med 169:309–314CrossRefGoogle Scholar
  26. 26.
    Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel W, Krammer PH, Runkel L (1995) Involvement of CD95 (APO-1/Fas) receptor and ligand in liver damage. J Exp Med 182:1223–1230PubMedCrossRefGoogle Scholar
  27. 27.
    Strand S, Hofmann WJ, Hug H, Muller M, Otto G, Strand D, Mariani SM, Stremmel W, Krammer PH, Galle PR (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumour cells-a mechanism of immune evasion? Nat Med 2:1361–1366PubMedCrossRefGoogle Scholar
  28. 28.
    Griffith TS, Brunner T, Fletcher SM, Green DR, Ferguson TA (1995) Fas-ligand induced apoptosis as a mechanism of immune privilege. Science 17:1189–1192CrossRefGoogle Scholar
  29. 29.
    Van Pel A, Boon T (1982) Protection against nonimmunogenic mouse leukemia by an immunogenic variant obtained by mutagenesis. Proc Natl Acad Sci U S A 79:4718–4722PubMedCrossRefGoogle Scholar
  30. 30.
    Coley WB (1893) The treatment of malignant tumours by repeated inoculations of erysipelas with a report of 10 original cases. Am J Med Sci 105:487–511CrossRefGoogle Scholar
  31. 31.
    Order SE, Stillwagon GB, Klein JL, Leichner PK, Siegelman SS, Fishman EK, Ettinger DS, Haulk T, Kopher K, Finney K et al (1985) Iodine 131 antiferritin, a new treatment modality in hepatoma: A Radiation Therapy Oncology Group Study. J Clin Oncol 3:1573–1582PubMedGoogle Scholar
  32. 32.
    Nayersina R, Fowler P, Guilhot S, Missale G, Cerny A, Schlicht HJ, Vitiello A, Chesnut R, Person JL, Redeker AG, Chisari FV (1993) HLA-A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during B infection. J Immunol 150:4659–4671PubMedGoogle Scholar
  33. 33.
    Galun E, Shouval D, Adler R, Shahaar M, Wilchek M, Hurwitz E, Sela M (1990) The effect of anti-α-fetoprotein-adriamycin conjugate on a human hepatoma. Hepatology 11:578–584PubMedCrossRefGoogle Scholar
  34. 34.
    Welt S, Scott AM, Divgi CR, Kemeny NE, Finn RD, Daghighian F, Germain JS, Richards EC, Larson SM, Old LJ (1996) Phase I/II study of iodine-125-labeled monoclonal antibody A33 in patients with advanced colon Cancer. J Clin Oncol 14:1573–1562Google Scholar
  35. 35.
    Bos JL (1989) Ras Oncogenes in human cancer: a review. Cancer Res 49:4682–4689PubMedGoogle Scholar
  36. 36.
    Barnd DL, Lan MS, Metzgar RS, Finn OJ (1989) Specific MHC-unrestricted recognition of tumour associated mucins by human cytotoxic cells. Proc Natl Acad Sci U S A 86:7159–7163PubMedCrossRefGoogle Scholar
  37. 37.
    Tomlinson I, IIyas M, novella M (1997) Molecular genetics of colon cancer. Cancer Metastasis Rev 16:67–79PubMedCrossRefGoogle Scholar
  38. 38.
    Thompson JA, Grumert F, Zimmermann W (1991) Carcinoembryonic antigen gene family: molecular biology and clinical prospectives. J Clin Lab Anal 5:344–366PubMedCrossRefGoogle Scholar
  39. 39.
    Riethmuller G, Schneider-Gadicke E, Schlimok G et al (1994) Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes’ C colorectal carcinoma: German Cancer Aid 17-1A Study Group. Lancet 343:1177–1183PubMedCrossRefGoogle Scholar
  40. 40.
    Chiriva-Internati M, Grizzi F, Bright RK, Kast WM (2004) Cancer immunotherapy: avoiding the road to perdition. J Transl Med 2:26PubMedCrossRefGoogle Scholar
  41. 41.
    Sallusto F, Lanzavecchia A (1994) Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony stimulating factor plus interleukin 4 and down regulated by tumour necrosis factor alpha. J Exp Med 17:1109–1111CrossRefGoogle Scholar
  42. 42.
    Arthur JF, Butterfield LH, Roth MD, Bui LA, Kiertscher SM, Lau R, Dubinett S, Glaspy J, McBride WH, Economou JSP (1997) A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther 4:17–25PubMedGoogle Scholar
  43. 43.
    Meyer zum Buschenfelde C, Nicklisch N, Rose-John S Peschel C, Bernhard H (2000) Generation of tumour-reactive CTL against the tumour-associated antigen HER2 using retrovirally transduced dendritic cells derived from CD34+ hemopoietic progenitor cells. J Immunol 165:4133–4140PubMedGoogle Scholar
  44. 44.
    Zhao L, Mou DC, Leng XS, Peng JR, Wang WX, Huang L, Li S, Zhu JY (2004) Expression of cancer-testis antigens in hepatocellular carcinoma. World J Gastroenterol 10:2034–2038PubMedGoogle Scholar
  45. 45.
    Wu LQ, Lu Y, Wang XF, Lv ZH, Zhang B, Yang JY (2006) Expression of cancer-testis antigen (CTA) in tumour tissues and peripheral blood of Chinese patients with hepatocellular carcinoma. Life Sci 79:744–748PubMedCrossRefGoogle Scholar
  46. 46.
    Peng JR, Chen HS, Mou DC, Cao J, Cong X, Qin LL, Wei L, Leng XS, Wang Y, Chen WF (2005) Expression of cancer/testis (CT) antigens in Chinese hepatocellular carcinoma and its correlation with clinical parameters. Cancer Lett 219:223–232PubMedCrossRefGoogle Scholar
  47. 47.
    Yin YH, Li YY, Qiao H, Wang HC, Yang XA, Zhang HG, Pang XW, Zhang Y, Chen WF (2005) TSPY is a cancer testis antigen expressed in human hepatocellular carcinoma. Br J Cancer 93:458–463PubMedCrossRefGoogle Scholar
  48. 48.
    Zhang WM, Xiao G, Zhang M, Guo AL, Dong Y, Wen JM (2005) Expression of NY-ESO-1 and LAGE-1 cancer-testis antigens in hepatocellular carcinoma. Zhonghua Bing Li Xue Za Zhi 34:202–205PubMedGoogle Scholar
  49. 49.
    Zhang WM, Xiao G, Xie D, Zhang M, Guo AL, Wen JM (2005) Correlation of NY-ESO-1 gene and protein expression to metastasis and clinicopathologic features of hepatocellular carcinoma. Ai Zheng 24:622–626PubMedGoogle Scholar
  50. 50.
    Shi YY, Wang HC, Yin YH, Sun WS, Li Y, Zhang CQ, Wang Y, Wang S, Chen WF (2005) Identification and analysis of tumour-associated antigens in hepatocellular carcinoma. Br J Cancer 92:929–934PubMedCrossRefGoogle Scholar
  51. 51.
    Li B, Qian XP, Pang XW, Zou WZ, Wang YP, Wu HY, Chen WF (2003) HCA587 antigen expression in normal tissues and cancers: correlation with tumour differentiation in hepatocellular carcinoma. Lab Invest 83:1185–1192PubMedCrossRefGoogle Scholar
  52. 52.
    Luo G, Huang S, Xie X, Stockert E, Chen YT, Kubuschok B, Pfreundschuh M (2002) Expression of cancer-testis genes in human hepatocellular carcinomas. Cancer Immun 2:11PubMedGoogle Scholar
  53. 53.
    Chiriva-Internati M, Wang Z, Pochopien S, Salati E, Lim SH (2003) Identification of a sperm protein 17 CTL epitope restricted by HLA-A1. Int J Cancer 107:863–865PubMedCrossRefGoogle Scholar
  54. 54.
    McClusky DA 3rd, Skandalakis LJ, Colborn GL, Skandalakis JE (1997) Hepatic surgery and hepatic surgical anatomy: historical partners in progress. World J Surg 21:330–342PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2007

Authors and Affiliations

  • Maurizio Chiriva-Internati
    • 1
  • Fabio Grizzi
    • 2
  • Mitchell S. Wachtel
    • 3
  • Marjorie Jenkins
    • 4
  • Raffaele Ferrari
    • 1
  • Everardo Cobos
    • 5
  • Eldo E. Frezza
    • 6
  1. 1.Department of Microbiology and ImmunologyTexas Tech University Health Science CenterLubbockUSA
  2. 2.Laboratori di Medicina Quantitativa, Istituto Clinico Humanitas IRCCSRozzano, MilanItaly
  3. 3.Department of PathologyTexas Tech University Health Science CenterLubbockUSA
  4. 4.Department of Internal MedicineTexas Tech University Health Science CenterLubbockUSA
  5. 5.Department of Hematology and OncologyTexas Tech University Health Science CenterLubbockUSA
  6. 6.Department of SurgeryTexas Tech University Health Science CenterLubbockUSA

Personalised recommendations